John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Cambridge CB2 0PY, UK.
John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Cambridge CB2 0PY, UK.
Trends Neurosci. 2022 Jan;45(1):53-63. doi: 10.1016/j.tins.2021.10.014. Epub 2021 Nov 29.
Mitochondrial failure has long been associated with programmed axon death (Wallerian degeneration, WD), a widespread and potentially preventable mechanism of axon degeneration. While early findings in axotomised axons indicated that mitochondria are involved during the execution steps of this pathway, recent studies suggest that in addition, mitochondrial dysfunction can initiate programmed axon death without physical injury. As mitochondrial dysfunction is associated with disorders involving early axon loss, including Parkinson's disease, peripheral neuropathies, and multiple sclerosis, the findings that programmed axon death is activated by mitochondrial impairment could indicate the involvement of druggable mechanisms whose disruption may protect axons in such diseases. Here, we review the latest developments linking mitochondrial dysfunction to programmed axon death and discuss their implications for injury and disease.
线粒体功能障碍与轴突程序性死亡(Wallerian 变性,WD)密切相关,后者是一种广泛存在且可能可预防的轴突变性机制。虽然在切断轴突的轴突中早期的发现表明线粒体参与了该途径的执行步骤,但最近的研究表明,此外,线粒体功能障碍可以在没有物理损伤的情况下引发程序性轴突死亡。由于线粒体功能障碍与涉及早期轴突丢失的疾病有关,包括帕金森病、周围神经病和多发性硬化症,程序性轴突死亡是由线粒体损伤激活的这一发现可能表明存在可药物干预的机制,破坏这些机制可能在这些疾病中保护轴突。在这里,我们综述了将线粒体功能障碍与程序性轴突死亡联系起来的最新进展,并讨论了它们对损伤和疾病的影响。